Compare Gilead Sciences, Inc. (GILD) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X Lithium & Battery Tech ETF — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Global X Lithium & Battery Tech ETF trades at $75. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Global X Lithium & Battery Tech ETF pays none, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | LIT | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $91.62 |
52-Week Low | $110.56 | $44.96 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LIT trades at $74.01, up 2.21% today, with bullish technical signals from moving averages but caution from oscillators. The stock has doubled over the past year, driven by strong momentum in electric vehicles, energy storage, and semiconductors. Recent news highlights global EV sales growth and China's ambitious 30% fleet target by 2030, supporting the lithium and battery technology theme.
Outlook remains positive given structural EV adoption trends, though overbought RSI levels suggest near-term consolidation risk. Key risks include Chinese export controls, regulatory changes, and competitive pressures. Analyst sentiment is constructive with buy ratings emphasizing long-term growth catalysts in clean energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
